BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 20447725)

  • 1. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series.
    Bas M; Greve J; Stelter K; Bier H; Stark T; Hoffmann TK; Kojda G
    Ann Emerg Med; 2010 Sep; 56(3):278-82. PubMed ID: 20447725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors.
    Gallitelli M; Alzetta M
    Am J Emerg Med; 2012 Oct; 30(8):1664.e1-2. PubMed ID: 22100478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of icatibant in ACE-inhibitor-induced angioedema.
    Baş M; Greve J; Stelter K; Havel M; Strassen U; Rotter N; Veit J; Schossow B; Hapfelmeier A; Kehl V; Kojda G; Hoffmann TK
    N Engl J Med; 2015 Jan; 372(5):418-25. PubMed ID: 25629740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ACEI-related angioedema with icatibant: a case series.
    Bova M; Guilarte M; Sala-Cunill A; Borrelli P; Rizzelli GM; Zanichelli A
    Intern Emerg Med; 2015 Apr; 10(3):345-50. PubMed ID: 25666515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).
    Bork K; Frank J; Grundt B; Schlattmann P; Nussberger J; Kreuz W
    J Allergy Clin Immunol; 2007 Jun; 119(6):1497-503. PubMed ID: 17418383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
    Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Icatibant is a new treatment option in life-threatening angioedema triggered by angiotensin-converting enzyme inhibitor].
    Fast S; Henningsen E; Bygum A
    Ugeskr Laeger; 2011 Oct; 173(41):2574-5. PubMed ID: 21985837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icatibant in angiotensin-converting enzyme (ACE) inhibitor-associated angioedema.
    Fok JS; Katelaris CH; Brown AF; Smith WB
    Intern Med J; 2015 Aug; 45(8):821-7. PubMed ID: 25944565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of angiotensin receptor blocker-induced angioedema: A case series.
    Strassen U; Bas M; Hoffmann TK; Knopf A; Greve J
    Laryngoscope; 2015 Jul; 125(7):1619-23. PubMed ID: 25646708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant.
    Schmidt PW; Hirschl MM; Trautinger F
    J Am Acad Dermatol; 2010 Nov; 63(5):913-4. PubMed ID: 20554347
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.
    Straka BT; Ramirez CE; Byrd JB; Stone E; Woodard-Grice A; Nian H; Yu C; Banerji A; Brown NJ
    J Allergy Clin Immunol; 2017 Jul; 140(1):242-248.e2. PubMed ID: 27913306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: A meta-analysis of randomized controlled trials.
    Jeon J; Lee YJ; Lee SY
    J Clin Pharm Ther; 2019 Oct; 44(5):685-692. PubMed ID: 31290163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant.
    Del Corso I; Puxeddu I; Sardano E; Geraci S; Breggia M; Rocchi V; Migliorini P
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):460-1. PubMed ID: 22626601
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bradykinin-mediated angioedema secondary to angiotensin converting enzyme: initiate treatment from the prehospital phase].
    Javaud N; Fain O; Bernot B; Adnet F; Lapostolle F
    Ann Fr Anesth Reanim; 2011 Nov; 30(11):848-50. PubMed ID: 21978477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor-Induced Angioedema.
    Culley CM; DiBridge JN; Wilson GL
    Ann Pharmacother; 2016 Jan; 50(1):47-59. PubMed ID: 26416949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema.
    Sinert R; Levy P; Bernstein JA; Body R; Sivilotti MLA; Moellman J; Schranz J; Baptista J; Kimura A; Nothaft W;
    J Allergy Clin Immunol Pract; 2017; 5(5):1402-1409.e3. PubMed ID: 28552382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
    Greve J; Hoffmann TK; Schuler P; Lang S; Chaker A; Bas M
    Int J Dermatol; 2011 Oct; 50(10):1294-5. PubMed ID: 21950301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study.
    Zanichelli A; Bova M; Coerezza A; Petraroli A; Triggiani M; Cicardi M
    Allergy; 2012 Aug; 67(8):1074-7. PubMed ID: 22686628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icatibant for the treatment of hereditary angioedema.
    Cole SW; Lundquist LM
    Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors.
    Scalese MJ; Reinaker TS
    Am J Health Syst Pharm; 2016 Jun; 73(12):873-9. PubMed ID: 27261237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.